Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection

Journal of Hepatology

Volumn 58, Issue 4, 2013, Pages 669-675

  Rau, Monika ^a,b   Stickel, Felix ^c   Russmann, Stefan ^a,g   Manser, Christine N ^a   Becker, Philip P ^a   Weisskopf, Michael ^a   Schmitt, Johannes ^a,b   Dill, Michael T ^d   Dufour, Jean François ^c   Moradpour, Darius ^e   Semela, David ^f   Müllhaupt, Beat ^a,g   Geier, Andreas ^a,b,g  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^g UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Anemia; Chronic hepatitis C; ITPA; Ribavirin; SLC28 transporters; Therapy response

Indexed keywords

BOCEPREVIR; GLUCOSE TRANSPORTER; HEMOGLOBIN; INOSINE TRIPHOSPHATASE; NUCLEOSIDE TRANSPORTER; PEGINTERFERON; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; RIBAVIRIN; SLC28A2 PROTEIN; SLC28A3 PROTEIN; TELAPREVIR; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ANTIBODY RESPONSE; ARTICLE; BODY WEIGHT; COHORT ANALYSIS; CONTROLLED STUDY; DNA ISOLATION; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANEMIA; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; HEMOGLOBINS; HEPATITIS C, CHRONIC; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYROPHOSPHATASES; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84880932942     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.11.027     Document Type: Article

References (33)

1. L. Gravitz Introduction: a smouldering public-health crisis Nature 474 2011 S2 S4
2. J.H. Hoofnagle, and L.B. Seeff Peginterferon and ribavirin for chronic hepatitis C N Engl J Med 355 2006 2444 2451 (Pubitemid 44903748)
3. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Goncales Jr Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
4. R. Kubota, T. Komiyama, N. Kumagai, M. Kimijima, K. Mitsuki, and J. Uetake Optimal erythrocyte ribavirin level to reduce the risk of anemia and obtain an early virological response in patients with chronic hepatitis C caused by genotype 1b infection Hepat Res Treat 2010 2010 495928
5. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965 (Pubitemid 32913521)
6. S. Russmann, I. Grattagliano, P. Portincasa, V.O. Palmieri, and G. Palasciano Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research Curr Med Chem 13 2006 3351 3357 (Pubitemid 44669779)
7. J.G. McHutchison, M.P. Manns, and D.L. Longo Definition and management of anemia in patients infected with hepatitis C virus Liver Int 26 2006 389 398
8. G.L. Davis, J.B. Wong, J.G. McHutchison, M.P. Manns, J. Harvey, and J. Albrecht Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C Hepatology 38 2003 645 652 (Pubitemid 37052151)
9. M.S. Sulkowski, M.L. Shiffman, N.H. Afdhal, K.R. Reddy, J. McCone, and W.M. Lee Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate Gastroenterology 139 2010 1602 1611 1611 e1601
10. J. Fellay, A.J. Thompson, D. Ge, C.E. Gumbs, T.J. Urban, and K.V. Shianna ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C Nature 464 2010 405 408
11. N. von Ahsen, M. Oellerich, and V.W. Armstrong Characterization of the inosine triphosphatase (ITPA) gene: haplotype structure, haplotype-phenotype correlation and promoter function Ther Drug Monit 30 2008 16 22 (Pubitemid 351161094)
12. J.H. Fraser, H. Meyers, J.F. Henderson, L.W. Brox, and E.E. McCoy Individual variation in inosine triphosphate accumulation in human erythrocytes Clin Biochem 8 1975 353 364
13. L. De Franceschi, G. Fattovich, F. Turrini, K. Ayi, C. Brugnara, and F. Manzato Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage Hepatology 31 2000 997 1004 (Pubitemid 30169949)
14. I. Grattagliano, S. Russmann, V.O. Palmieri, P. Juni, F. Bihl, and P. Portincasa Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C Hepatology 39 2004 1248 1255 (Pubitemid 38569046)
15. Y. Hitomi, E.T. Cirulli, J. Fellay, J.G. McHutchison, A.J. Thompson, and C.E. Gumbs Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function Gastroenterology 140 2011 1314 1321
16. R.P. Owen, J.H. Gray, T.R. Taylor, E.J. Carlson, C.C. Huang, and M. Kawamoto Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2 Pharmacogenet Genomics 15 2005 83 90 (Pubitemid 40562985)
17. H.C. Shin, C.P. Landowski, D. Sun, B.S. Vig, I. Kim, and S. Mittal Functional expression and characterization of a sodium-dependent nucleoside transporter hCNT2 cloned from human duodenum Biochem Biophys Res Commun 307 2003 696 703 (Pubitemid 36944989)
18. +-nucleoside purine (N1) transporter Pharm Res 15 1998 950 952 (Pubitemid 28307840)
19. A. D'Avolio, A. Ciancio, M. Siccardi, L. Baietto, M. Simiele, and S. Patanella SLC28A2 65C>T predict sustained virological response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4 Vienna: EASL J Hepatol 2010 S463
20. +-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib) J Biol Chem 276 2001 2914 2927
21. A. Doehring, W.P. Hofmann, C. Schlecker, S. Zeuzem, C. Sarrazin, and T. Berg Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C Pharmacogenet Genomics 21 2011 289 296
22. L. Prasad, V.M. Spicher, M. Zwahlen, M. Rickenbach, B. Helbling, and F. Negro Cohort profile: the Swiss Hepatitis C Cohort Study (SCCS) Int J Epidemiol 36 2007 731 737 (Pubitemid 47394136)
23. J.F. Jen, P. Glue, S. Gupta, D. Zambas, and G. Hajian Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C Ther Drug Monit 22 2000 555 565
24. V. Loustaud-Ratti, S. Alain, A. Rousseau, I.F. Hubert, F.L. Sauvage, and P. Marquet Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C Hepatology 47 2008 1453 1461 (Pubitemid 351702729)
25. M.K. Jain, and C. Zoellner Role of ribavirin in HCV treatment response: now and in the future Expert Opin Pharmacother 11 2010 673 683
26. M. Kurosaki, Y. Tanaka, K. Tanaka, Y. Suzuki, Y. Hoshioka, and N. Tamaki Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin Antivir Ther 16 2011 685 694
27. T. Nishimura, R. Osaki, M. Shioya, H. Imaeda, T. Aomatsu, and T. Takeuchi Polymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced anemia in chronic hepatitis C patients Mol Med Rep 5 2012 517 520
28. N. Sakamoto, Y. Tanaka, M. Nakagawa, H. Yatsuhashi, S. Nishiguchi, and N. Enomoto ITPA gene variant protects against anemia induced by pegylated interferon-alpha and ribavirin therapy for Japanese patients with chronic hepatitis C Hepatol Res 40 2010 1063 1071
29. F. Suzuki, Y. Suzuki, N. Akuta, H. Sezaki, M. Hirakawa, and Y. Kawamura Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir Hepatology 53 2011 415 421
30. M. Kurosaki, Y. Tanaka, K. Tanaka, Y. Suzuki, Y. Hoshioka, and N. Tamaki Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin Antivir Ther 16 2011 685 694
31. A.J. Thompson, J. Fellay, D. Ge, T. Urban, K. Shianna, and M. Sulkowski Genome wide analysis of patients from the IDEAL study identifies a causal role for ITPA gene variation in ribavirin induced hemolytic anemia Vienna: EASL J Hepatol 2010 S470
32. S. Zeuzem, V. Soriano, T. Asselah, J.P. Bronowicki, E. Ceausus, and E.W. Lohse Virological response to an interferon-free refimen of BI201335 and BI207127, with and withourt ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: week 12 interim results of the SOUND-C2 study San Francisco: AASLD Hepatology 2011 1436A
33. S. Zeuzem, P. Buggisch, K. Agarwal, P. Marcellin, D. Sereni, and H. Klinker The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C Hepatology 55 2012 749 758